ClinicalTrials.gg
RecruitingNCT04888481Updated May 11, 2026

68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

A Phase 2 interventional study of 68Ga-HA-DOTATATE in Neuroendocrine Tumors, sponsored by University of Alberta. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by University of Alberta · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
600
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Neuroendocrine Tumors with a site in Canada — 11 open to participants now, 20 under way, 4 of them phase 3. Neuroendocrine Tumors · Canada.

Planned enrollment
6th of 33
600 · median 160
Started
2022
with 3 others
Phase 2
13 of 42
2 open now
Primary completion
2027-08
later than 12 of 19 live
Registered
33rd of 42
by date
Lead sponsor
4 of 42
University of Alberta

Among the 42 studies in Neuroendocrine Tumors with a site in Canada, this one is the 6th largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2022, is one of 13 in phase 2, reaches primary completion later than 12 of the 19 other live ones, and was the 33rd registered.

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

11 of the 42 studies in Neuroendocrine Tumors with a site in Canada are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Neuroendocrine Tumors with a site in Canada, or all of them as a file.
02

Study summary

Somatostatin receptor (SSR) imaging is a critical component of clinical care for many patients being investigated for or with confirmed SSR positive tumors. In the past, 111In-octreotide imaging has been used for this purpose but it has been recently supplanted globally by SSR positron emission tomography (PET) imaging due to better image quality and higher diagnostic accuracy.

This study will assess the safety and diagnostic effectiveness of 68Ga-HA-DOTATATE produced a the Edmonton Radiopharmaceutical Centre (ERC).

Read the detailed description

A single centre non-randomized, non-blinded phase II prospective cohort study evaluating the safety and efficacy of 68Ga-HA-DOTATATE PET/CT imaging in patients with known or suspected somatostatin receptor positive tumors.

Up to 600 scans will be included over 6 years. All patient ages (pediatric and adult) will be included. Individual patients may have more than one scan during the study period.

Safety evaluation will consist of an adverse event assessment whil in the Nuclear Medicine department at the University of Alberta Hospital. Efficacy evaluation will consist of a comparison to CT and/or MRI accuracy based on 1 year follow-up clinical evaluation.

03

Conditions studied

  • Neuroendocrine Tumors

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with known or clinically suspected somatostatin receptor positive tumors including but not limited to: gastrointestinal neuroendocrine tumors, pancreatic neuroendocrine tumors, pulmonary neuroendocrine tumors, neuroendocrine tumors - primary unknown, pheochromocytoma, paraganglioma, medullary thyroid cancer, medulloblastoma, meningioma
  • A standard clinical CT or MRI is obtained within 6 months of enrollment
  • Ability to provide written prior to participation in the study (participant or if required a legal medical decision maker)

Exclusion criteria

Exclusion Criteria:

  • Weight > 225 kg (weight limit of the PET/CT scanner)
  • Inability to scan (ie. extreme claustrophobia) or inability to lie still for imaging
  • Any additional medical condition, serious inter-current illness, or other extenuating circumstance that, in the opinion of the investigator or attending department physician, may significantly interfere with study performance or interpretation
  • Previous allergic reaction to DOTATATE or somatostatin analogues
  • Lack of intravenous access
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    68Ga-HA-DOTATATE PET/CT scan

    2.64 MBq/kg (minimum 37 MBq, maximum 250 MBq) 68Ga-HA-DOTATATE intravenous single-dose administration for PET/CT imaging

    Drug: 68Ga-HA-DOTATATE

Interventions

  • Drug68Ga-HA-DOTATATE

    Tracer injection

06

What researchers measure

Primary outcomes

  1. Efficacy - sensitivity

    Sensitivity of 68Ga-HA-DOTATATE PET/CT compared to 1 year clinical follow-up

    Time frame: 1 year post-scan

  2. Efficacy - specificity

    Specificity of 68Ga-HA-DOTATATE PET/CT compared to 1 year clinical follow-up

    Time frame: 1 year post-scan

Secondary outcomes

  1. Safety - adverse events - immediate

    Assessment of adverse events immediately after tracer injection

    Time frame: Immediately (within 15 minutes) after tracer injection

  2. Safety - adverse events - post-scan

    Assessment of adverse events immediately after PET/CT scan

    Time frame: Immediately (within 15 minutes) after PET/CT scan; 60 to 100 minutes after tracer injection

  3. Safety - adverse events - delayed

    Self-reporting of possible adverse events after leaving the PET department

    Time frame: 10 days after tracer injection

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Aug 2027, 66 months after the start.

Of 85 non-industry phase 2 interventional studies under Neuroendocrine Tumors, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 83. This study's planned 66 months is close to that.

Counting every sponsor, half of 98 studies reached it within 65 months; a quarter within 42 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2021
First posted
May 17, 2021
StartActual
Feb 15, 2022
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2028
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04888481
Responsible party
Sponsor
First posted
May 17, 2021
Start date
Feb 15, 2022
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
May 11, 2026

Study contacts

Jonathan Abele, MD
Contact
jabele@ualberta.ca
780-407-6907
Jonathan Abele, MD
principal investigator · University of Alberta

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion